<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://dk.um.si/IzpisGradiva.php?id=88252"><dc:title>Učinkovitost zdravljenja sindroma policističnih jajčnikov z metforminom</dc:title><dc:creator>Jerenec,	Katja	(Avtor)
	</dc:creator><dc:creator>Samojlenko,	Maša	(Avtor)
	</dc:creator><dc:creator>Geršak,	Ksenija	(Avtor)
	</dc:creator><dc:creator>Ferk,	Polonca	(Avtor)
	</dc:creator><dc:subject>sindrom policističnih jajčnikov</dc:subject><dc:subject>metformin</dc:subject><dc:subject>farmakogenetika</dc:subject><dc:subject>osebna medicina</dc:subject><dc:description>Metformin is an oral antidiabetic drug with potentially beneficial effects in patients with polycystic ovary syndrome (PCOS). Different pharmacological responses to metformin have been reported in PCOS patients, which may be attribut able to various clinical, biochemical, genetic and other factors. Here, we have outlined a short review of the results from current clinical studies on metformin efficacy in PCOS patients. Additionally, preliminary results from a retrospective pharmacogenetic study by our group on a sample of Slovene PCOS patients are presented. Pharmacogenetics is an emerging science that should provide options for individualized medicine, the future of healthcare.</dc:description><dc:date>2013</dc:date><dc:date>2024-04-12 09:54:21</dc:date><dc:type>Znanstveno delo</dc:type><dc:identifier>88252</dc:identifier><dc:language>sl</dc:language></rdf:Description></rdf:RDF>